[
  {
    "ts": null,
    "headline": "3 “Forever Stocks” to Hold When the Market Won’t Sit Still",
    "summary": "Chevron, Colgate-Palmolive, and Merck highlight how dividends, durable businesses, and long-term growth drivers can support a buy-and-hold investment strategy",
    "url": "https://finnhub.io/api/news?id=3b3e95d23d25fd53b61c2a12d84ff5a6bdff14918a1dbc8fbf41b7fdfe571858",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768836660,
      "headline": "3 “Forever Stocks” to Hold When the Market Won’t Sit Still",
      "id": 138187454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Chevron, Colgate-Palmolive, and Merck highlight how dividends, durable businesses, and long-term growth drivers can support a buy-and-hold investment strategy",
      "url": "https://finnhub.io/api/news?id=3b3e95d23d25fd53b61c2a12d84ff5a6bdff14918a1dbc8fbf41b7fdfe571858"
    }
  },
  {
    "ts": null,
    "headline": "CytomX Stock Rises 31% in a Month: Here's What You Should Know",
    "summary": "CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.",
    "url": "https://finnhub.io/api/news?id=c9f2832a6ce58830b0db1e61a3f0309cacc0c0d92b6c5b9e4e66351971909b84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768832220,
      "headline": "CytomX Stock Rises 31% in a Month: Here's What You Should Know",
      "id": 138177976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.",
      "url": "https://finnhub.io/api/news?id=c9f2832a6ce58830b0db1e61a3f0309cacc0c0d92b6c5b9e4e66351971909b84"
    }
  },
  {
    "ts": null,
    "headline": "Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform",
    "summary": "PALO ALTO, Calif., January 19, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform.",
    "url": "https://finnhub.io/api/news?id=9294e0f3dd9f057589016f59c0e3ae00d5e696e39db9ce2fe3acf267cf616109",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768827900,
      "headline": "Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform",
      "id": 138177032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "PALO ALTO, Calif., January 19, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform.",
      "url": "https://finnhub.io/api/news?id=9294e0f3dd9f057589016f59c0e3ae00d5e696e39db9ce2fe3acf267cf616109"
    }
  },
  {
    "ts": null,
    "headline": "Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan",
    "summary": "Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.",
    "url": "https://finnhub.io/api/news?id=503f4b6fbb9bb2db559370a3732a67ffc25763a4cff27963a2a84b662fa84d15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768826280,
      "headline": "Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan",
      "id": 138177946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.",
      "url": "https://finnhub.io/api/news?id=503f4b6fbb9bb2db559370a3732a67ffc25763a4cff27963a2a84b662fa84d15"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck (MRK) Pricing Reflect Long Term Value After Recent Share Price Strength",
    "summary": "If you are wondering whether Merck's current share price reflects its true worth, this article walks through what the numbers are really saying about the stock. Merck's shares last closed at US$108.83, with a 7.7% return over the past 30 days and 15.3% over the last year, while the 7 day return was a 0.3% decline and the year to date return sits at 2.2%. The 3 year and 5 year returns are 8.5% and 64.8% respectively. Recent attention on Merck has been shaped by ongoing product developments...",
    "url": "https://finnhub.io/api/news?id=226f52f8ab2852b7818a64e6e3c53c3038943440e395ed37f503aa81547c7fad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768810273,
      "headline": "Is Merck (MRK) Pricing Reflect Long Term Value After Recent Share Price Strength",
      "id": 138175743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "If you are wondering whether Merck's current share price reflects its true worth, this article walks through what the numbers are really saying about the stock. Merck's shares last closed at US$108.83, with a 7.7% return over the past 30 days and 15.3% over the last year, while the 7 day return was a 0.3% decline and the year to date return sits at 2.2%. The 3 year and 5 year returns are 8.5% and 64.8% respectively. Recent attention on Merck has been shaped by ongoing product developments...",
      "url": "https://finnhub.io/api/news?id=226f52f8ab2852b7818a64e6e3c53c3038943440e395ed37f503aa81547c7fad"
    }
  },
  {
    "ts": null,
    "headline": "3 Profitable Stocks to Consider Right Now",
    "summary": "Profitable companies tend to be more resilient, giving them the flexibility to invest and return capital to shareholders. Businesses that consistently generate earnings can better navigate downturns and capitalize on new opportunities.",
    "url": "https://finnhub.io/api/news?id=918a7a3ea2d3a745b81f2b0bb656dfb1db0202670922e96130d5e6291c02e115",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768797336,
      "headline": "3 Profitable Stocks to Consider Right Now",
      "id": 138179028,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Profitable companies tend to be more resilient, giving them the flexibility to invest and return capital to shareholders. Businesses that consistently generate earnings can better navigate downturns and capitalize on new opportunities.",
      "url": "https://finnhub.io/api/news?id=918a7a3ea2d3a745b81f2b0bb656dfb1db0202670922e96130d5e6291c02e115"
    }
  }
]